Can mixed vaccination of COVID-19 vaccine work?

On December 20, 2021, the International Vaccine Institute (IVI), the Saúde National Institute (INS) in Mozambique and the Alliance for Epidemiological Prevention Innovation (CEPI) announced today that a phase II vaccine mixed-match trial has begun in Mozambique to study The main promotion scheme for using two different COVID-19 vaccines
.
In the case of vaccine shortage, if the second dose of vaccine is not necessarily the same as the first dose, the immunization schedule will be more flexible and may cause a wider protective immune response

The research was led by INS, supported by the trial sponsor International Institute of Immunology, and funded by the Epidemic Prevention Innovation Alliance
.
The study will use Sinopharm’s BBIBP-CorV and Johnson & Johnson’s Ad26.

Dr.
Florian Marks, Deputy Director-General of the International Institute of Vaccines and Chief Researcher of the International Institute of Vaccines, said: “Proving the safety and effectiveness of the COVID-19 vaccine mixing schedule will have a major impact on ensuring timely vaccination and control of the pandemic, especially In areas most severely affected by vaccine shortages
.
In the current global pandemic, access to vaccines is unfair and interrupted.

Dr.

Dr.
Melanie Saville, Director of Vaccine Research and Development of the Epidemic Prevention Initiative, said: “This trial will generate valuable data on the mix and match of the two vaccines, which is being promoted in many countries in Africa
.
It will support our efforts to expand vaccine access to vaccines.

This phase II clinical trial is a single-center, observer-blind, randomized study that aims to evaluate two different vaccine injection schedules with 28-day intervals and the use of two doses of BBIBP-CorV injection (same source) and a single dose of Ad26.

This trial is part of the ECOVA project, which aims to expand the availability of COVID-19 vaccines in Africa
.
The project was funded by the International Vaccine Institute at a cost of 12.

The ECOVA project is one of a series of programs funded by the Epidemiology and Immunization Alliance.
It aims to bridge the current and long-term gaps in clinical knowledge of vaccine performance, so as to expand the availability of COVID-19 vaccines and achieve global vaccine promotion
.
This funding is part of the next five-year plan of the Epidemic Prevention Initiative, which was announced in March 2021 to strengthen our defense against COVID-19 and reduce or even eliminate the risk of pandemics and epidemics in the future

Introduction to the International Vaccine Institute The International Vaccine Institute is a non-profit intergovernmental organization established in 1997 under the initiative of the United Nations Development Program (UNDP)
.
The International Institute of Vaccines has 36 countries and World Health Organization (WHO) treaties, including the Republic of Korea, Sweden, India and Finland as state sponsors
.
Its mission is to provide and obtain vaccines for the most vulnerable people in the world
.
Focus on infectious diseases of global health importance, such as cholera, typhoid fever, Shigella, salmonella, schistosomiasis, chikungunya, group A streptococcus, hepatitis A, human papillomavirus, tuberculosis, HIV , Middle East Respiratory Syndrome, COVID-19, and antimicrobial resistance
.
For more information, please visit https:// Saúde (INS)

The National Institute of Health Saúde is Mozambique’s National Public Health and Research Institute, an autonomous public entity under the Ministry of Health
.

About CEPI

The Epidemic Prevention Initiative is an innovative partnership between public, private, charitable, and civil organizations.
It was launched in Davos in 2017 to develop a vaccine to prevent future epidemics
.
Before the COVID-19 outbreak, the Alliance for Prevention of Innovation was committed to developing vaccines for Ebola virus, Lassa virus, Middle East respiratory syndrome coronavirus, Nipah virus, Rift Valley fever virus and Chikungunya virus.
The alliance has developed More than 20 candidate vaccines against these pathogens have been developed
.
The Epidemic Prevention Initiative also invests in new platform technologies for the rapid development of vaccines against unknown pathogens (Disease X)
.

During the current pandemic, the Epidemic Prevention Coalition has launched a number of programs to develop a vaccine against SARS-CoV-2 and its variants, with a focus on speed, scale, and accessibility
.
These plans make use of the rapid response platform and new cooperation developed by the partners of the Epidemic Prevention and Control Alliance before the emergence of COVID-19
.
Its purpose is to promote the clinical development of a diverse portfolio of safe and effective COVID-19 vaccine candidates, and to distribute these vaccines fairly across the world through the COVID-19 global access mechanism
.

CEPI’s 5-year plan sets out a $3.
5 billion roadmap to compress the vaccine development timeline to 100 days, develop a universal vaccine against COVID-19 and other beta-coronaviruses, and create one to combat known And a "library" of candidate vaccines for unknown pathogens
.
The program can http:// Read on
.